A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...

The discovery and development of drugs in pharmacological research – including the risk assessment of active substances in ...

These initiatives represent a way to accelerate access to treatments that have historically faced longer regulatory pathways.

This principle is an important basis for the development of antibiotics ... If the MEP pathway in bacteria is blocked, for example by a drug, the bacteria can no longer produce a number of ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

The pathway controls the production ... NXP800 has been granted designations from the US Food and Drug Administration (FDA) to speed up its development to potentially treat ARID1a-deficient ...

Washington — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and ...